Harpoon Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2023

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Harpoon Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2023.
Harpoon Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2023 was -$12.1M, a 2.1% decline year-over-year.
Harpoon Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2023 was -$39.1M, a 45% increase year-over-year.
Harpoon Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$68.3M, a 41.5% increase from 2021.
Harpoon Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$117M, a 127% decline from 2020.
Harpoon Therapeutics, Inc. annual Operating Income (Loss) for 2020 was -$51.3M, a 11.8% increase from 2019.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2023	-$39.1M	-$12.1M	-$250K	-2.1%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-09
Q2 2023	-$38.9M	$2.49M	+$19.9M		Apr 1, 2023	Jun 30, 2023	10-Q	2023-08-09
Q1 2023	-$58.8M	-$10.8M	+$9.55M	+47%	Jan 1, 2023	Mar 31, 2023	10-Q	2023-05-11
Q4 2022	-$68.3M	-$18.7M	+$2.83M	+13.1%	Oct 1, 2022	Dec 31, 2022	10-K	2023-03-27
Q3 2022	-$71.2M	-$11.9M	+$4.79M	+28.7%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-09
Q2 2022	-$75.9M	-$17.4M	-$643K	-3.84%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-09
Q1 2022	-$75.3M	-$20.3M	+$41.5M	+67.1%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-11
Q4 2021	-$117M	-$21.5M	-$10M	-87.4%	Oct 1, 2021	Dec 31, 2021	10-K	2023-03-27
Q3 2021	-$107M	-$16.7M	-$3.08M	-22.7%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-14
Q2 2021	-$104M	-$16.8M	-$3.66M	-27.9%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-10
Q1 2021	-$100M	-$61.8M	-$48.6M	-370%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-12
Q4 2020	-$51.3M	-$11.5M	+$3.31M	+22.3%	Oct 1, 2020	Dec 31, 2020	10-K	2021-03-10
Q3 2020	-$54.6M	-$13.6M	+$3.02M	+18.2%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-10
Q2 2020	-$57.7M	-$13.1M	-$465K	-3.68%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-05
Q1 2020	-$57.2M	-$13.1M	+$1.02M	+7.18%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-06
Q4 2019	-$58.2M	-$14.8M	-$4.94M	-50%	Oct 1, 2019	Dec 31, 2019	10-K	2021-03-10
Q3 2019	-$53.3M	-$16.6M	-$9.76M	-143%	Jul 1, 2019	Sep 30, 2019	10-K	2021-03-10
Q2 2019	-$43.5M	-$12.6M	-$6.59M	-109%	Apr 1, 2019	Jun 30, 2019	10-K	2021-03-10
Q1 2019	-$36.9M	-$14.2M	-$9.2M	-186%	Jan 1, 2019	Mar 31, 2019	10-K	2021-03-10
Q4 2018	-$27.7M	-$9.87M	-$4.87M	-97.6%	Oct 1, 2018	Dec 31, 2018	10-K	2020-03-12
Q3 2018	-$22.9M	-$6.85M	-$1.96M	-40.1%	Jul 1, 2018	Sep 30, 2018	10-K	2020-03-12
Q2 2018	-$20.9M	-$6.06M	-$2.41M	-66%	Apr 1, 2018	Jun 30, 2018	10-K	2020-03-12
Q1 2018	-$18.5M	-$4.95M	-$1.96M	-65.3%	Jan 1, 2018	Mar 31, 2018	10-K	2020-03-12
Q4 2017	-$16.5M	-$5M			Oct 1, 2017	Dec 31, 2017	10-K	2019-03-14
Q3 2017		-$4.89M			Jul 1, 2017	Sep 30, 2017	10-K	2019-03-14
Q2 2017		-$3.65M			Apr 1, 2017	Jun 30, 2017	10-K	2019-03-14
Q1 2017		-$3M			Jan 1, 2017	Mar 31, 2017	10-K	2019-03-14

* An asterisk sign (*) next to the value indicates that the value is likely invalid.